MYGN · Myriad Genetics Inc
$3.03
-0.14 (-4.42%)
At close · Aug 14
Market Cap
$289.82M
Shares
95.65M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$824.5M
-1.6%
FY2025
Net Income
-$365.9M
-187.4%
FY2025
Gross Margin
69.93%
0pp
FY2025
Operating Margin
-46.96%
-32.2pp
FY2025
Diluted EPS
-$3.95
-180.1%
FY2025
Operating Cash Flow
$1.8M
+120.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $806.6M | $824.5M | $837.6MG | $753.2M | $678.4M | $690.6M | $557.1M | $851.1M | $772.6M | $771.4M | $753.8M | $723.1M | $778.22M | $613.17M | $496.01M | $402.08M | |
| $251.4M | $247.9M | $252.2M | $236.2M | $202M | — | — | — | — | $145.2M | $132.8M | $132.8M | $96.14M | $64.38M | $51.45M | $45.64M | |
| $555.2M | $576.6M | $585.4M | $517M | $476.4M | — | — | — | — | — | — | — | — | — | — | — | |
| — | 69.93% | 69.89% | 68.64% | 70.22% | — | — | — | — | — | — | — | — | — | — | — | |
| $105.8M | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M | $73.3M | $85.9M | $70.8M | $74.4M | $70.6M | $75.5M | $67.48M | $53.71M | $42.65M | $27.75M | |
| $296.4M | $280.8M | $284.1M | $289.2M | $266.8M | — | — | — | — | — | — | — | — | — | — | — | |
| $243.5M | $256.8M | $275.9M | $283.7M | $247.9M | — | — | — | — | — | — | — | — | — | — | — | |
| $569M | — | — | $572.9M | $514.7M | $537.8M | $496.9M | $555.5M | $467.1M | $476.4M | $359.1M | $366M | $327.1M | $251.84M | $208.38M | $169.84M | |
| $31.6M | $34.7M | $42.1M | $42.8M | $41.1M | $50.7M | $61M | $59.3M | $37.3M | $33.3M | $12.6M | $12.7M | $4.63M | $895K | $7.15M | $7.15M | |
| — | $53.7M | $61.2M | $61.9M | $52.7M | $62.8M | $72M | $73M | $54.4M | $48.3M | $26.7M | $25M | $13.82M | $8.89M | $9.07M | $7.22M | |
| $653.8M | $963.8M | $708.9M | $774.4M | $617M | — | — | — | — | — | — | — | — | — | — | — | |
| $939.4M | — | — | $1.01B | $819M | $881.1M | $846.8M | $843.5M | $653.9M | $722M | $587M | $588.9M | $503.77M | $385.16M | $315.69M | $244.31M | |
| -$98.6M | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M | -$289.7M | $7.6M | $118.7M | $49.4M | $166.8M | $134.2M | $274.44M | $228M | $180.32M | $157.78M | |
| — | -46.96% | -14.74% | -34.17% | -20.73% | -27.58% | -52% | 0.89% | 15.36% | 6.4% | 22.13% | 18.56% | 35.27% | 37.18% | 36.35% | 39.24% | |
| — | -$333.5M | -$62.3M | -$195.5M | -$87.9M | -$127.7M | -$217.7M | $80.6M | $173.1M | $97.7M | $193.5M | $159.2M | $288.26M | $236.89M | $189.39M | $165M | |
| $16.4M | $10.5M | $2.8M | $2.9M | $3.2M | $6.6M | $11.2M | $12M | $3.2M | $6M | — | — | — | — | — | — | |
| $2.4M | $1.8M | $1.7M | $2.5M | $2.6M | $700K | $2M | $3.2M | $1.8M | $1.2M | $900K | $400K | $5.4M | $5.5M | $4.63M | $2.23M | |
| -$13.2M | -$7.9M | $0 | -$4.8M | $0 | $133.4M | $6.1M | -$7.6M | -$1.8M | -$6.5M | $2.1M | $700K | $3.42M | $5.27M | — | — | |
| -$111.8M | -$395.1M | -$123.5M | -$262.2M | -$140.6M | -$57.1M | -$283.6M | $0 | $116.9M | $42.9M | $168.9M | $134.9M | $277.87M | $233.28M | $184.54M | $159.65M | |
| $800K | -$29.2M | $3.8M | $1.1M | -$28.6M | -$29.9M | -$59.9M | -$4.4M | -$14M | $21.3M | $43.6M | $54.7M | $101.64M | $86.14M | $72.39M | $58.94M | |
| -$112.6M | -$365.9M | -$127.3M | -$263.3M | -$112M | -$27.2M | -$223.6M | $4.6M | $131.1M | $21.8M | $125.3M | $80.2M | $176.23M | $147.14M | $112.15M | $100.71M | |
| — | -44.38% | -15.2% | -34.96% | -16.51% | -3.94% | -40.14% | 0.54% | 16.97% | 2.83% | 16.62% | 11.09% | 22.64% | 24% | 22.61% | 25.05% | |
| — | — | — | — | $0 | $0 | -$100K | -$200K | -$200K | -$200K | — | — | — | — | — | — | |
| -$111.7M | -$364.3M | -$124.4M | -$258.1M | -$115.8M | -$30M | -$199.4M | $3.3M | $132.6M | $25.8M | $122.8M | $74.7M | $175.13M | $146.88M | $111.84M | $100.72M | |
| USD/shares | — | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | $0.06 | $1.89 | $0.32 | $1.79 | $1.12 | $2.33 | $1.82 | $1.33 | $1.12 |
| USD/shares | — | -$3.95 | -$1.41 | -$3.18 | -$1.39 | -$0.35 | -$2.99 | $0.06 | $1.82 | $0.32 | $1.71 | $1.08 | $2.25 | $1.77 | $1.30 | $1.10 |
| shares | — | 92.6M | 90.6M | 82.8M | 80.6M | 78M | 74.8M | 73.5M | 69.4M | 68.3M | 70M | 71.3M | 75.73M | 80.95M | 84.61M | 89.79M |
| shares | — | 92.6M | 90.6M | 82.8M | 80.6M | 78M | 74.8M | 76M | 72M | 68.8M | 73.4M | 74.5M | 78.18M | 83.33M | 86.47M | 91.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2021: $1.25B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.37×
Peer median 2.24×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 13 similar-size Diagnostics & Research companies (of 49 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2020 | FY2019 | FY2018 |
|---|---|---|---|
| Diagnostics | $593,500,000 | $789,400,000 | $690,400,000 |
| All Other Segments | $45,100,000 | $61,700,000 | $53,300,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $768,000,000 | $769,500,000 | $671,700,000 | $591,500,000 | $603,700,000 | $596,200,000 | $805,400,000 |
| Non Us | $56,500,000 | $68,100,000 | $81,500,000 | $86,900,000 | $86,900,000 | $42,400,000 | $45,700,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Hereditary Cancer | $372,400,000 | $364,500,000 | $327,800,000 | $305,500,000 | — | — | — | — |
| Prenatal | $186,300,000 | $177,100,000 | $151,300,000 | $116,400,000 | — | — | — | — |
| Mental Health | $144,100,000 | $170,200,000 | $138,500,000 | — | — | — | — | — |
| Tumor Profiling | $121,700,000 | $125,800,000 | $135,600,000 | $128,600,000 | $120,900,000 | — | $48,300,000 | — |
| Autoimmune | — | — | — | $300,000 | $28,200,000 | — | $39,100,000 | — |
| Hereditary Cancer Testing | — | — | — | — | $316,300,000 | — | $347,400,000 | — |
| Molecular Diagnostic Autoimmune | — | — | — | — | $28,200,000 | — | $39,100,000 | $48,300,000 |
| Molecular Diagnostic EndoPredict Testing | — | — | — | — | — | — | $10,500,000 | $10,400,000 |
| Molecular Diagnostic Genesight Testing | — | — | — | — | — | — | $74,100,000 | $112,600,000 |
| Molecular Diagnostic Hereditary Cancer Testing | — | — | — | — | $316,300,000 | — | $347,400,000 | $479,700,000 |
| Molecular Diagnostic Other Testing | — | — | — | — | $500,000 | — | $1,300,000 | $900,000 |
| Molecular Diagnostic Pharmacogenomics | — | — | — | — | $93,700,000 | — | $74,100,000 | $112,600,000 |
| Molecular Diagnostic Prenatal Testing | — | — | — | — | $106,800,000 | — | $76,700,000 | $104,900,000 |
| Molecular Diagnostic Prolaris Testing | — | — | — | — | — | — | $24,700,000 | $25,500,000 |
| Molecular Diagnostic Testing | — | — | — | — | $666,400,000 | $513,500,000 | $586,900,000 | $789,400,000 |
| Molecular Diagnostic Tumor Profiling | — | — | — | — | $120,900,000 | — | $48,300,000 | $43,000,000 |
| Molecular Diagnostic Vectra Testing | — | — | — | — | — | — | $39,100,000 | $48,300,000 |
| Other Testing | — | — | — | — | $500,000 | — | $1,300,000 | — |
| Pharmaceutical and Clinical Services | — | — | — | — | $24,200,000 | $43,600,000 | $51,700,000 | $61,700,000 |
| Pharmacogenomics | — | — | — | $127,600,000 | $93,700,000 | — | $74,100,000 | — |
| Prenatal Testing | — | — | — | — | $106,800,000 | — | $76,700,000 | — |
| Testing Revenue | — | — | — | — | $666,400,000 | — | $586,900,000 | — |
| Product And Service Other | — | — | — | — | $24,200,000 | — | $51,700,000 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2020 | FY2019 | FY2018 |
|---|---|---|---|
| Diagnostics | -$82,400,000 | $133,300,000 | $142,600,000 |
| All Other Segments | -$149,300,000 | -$125,700,000 | -$20,700,000 |
Operating Margin by Segment (%)
| Component | FY2020 | FY2019 | FY2018 |
|---|---|---|---|
| Diagnostics | -13.9% | 16.9% | 20.7% |
| All Other Segments | -331% | -203.7% | -38.8% |
Key facts
CIK
899923
CUSIP
62855J104
13F (30d)
193 filings
188 filers
Visit website
Investor relations